Description: Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Home Page: www.personalis.com
PSNL Technical Analysis
1330 O’Brien Drive
Menlo Park,
CA
94025
United States
Phone:
650 752 1300
Officers
| Name | Title |
|---|---|
| Mr. John Stephen West | Co-Founder, CEO, Pres & Director |
| Mr. Aaron L. Tachibana | Sr. VP & CFO |
| Dr. Richard Chen M.D., M.S., MS | Sr. VP of R&D and Chief Medical Officer |
| Dr. Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Atul Butte | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Michael Snyder Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Ms. Carol J. Tillis | VP of Fin. & Admin. |
| Mr. Stephen M. Moore J.D. | VP, Gen. Counsel & Corp. Sec. |
| Mr. Michael J Fitzpatrick | VP of Worldwide Sales |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5121 |
| Price-to-Sales TTM: | 1.5322 |
| IPO Date: | 2019-06-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 325 |